NITINOL MEDICAL TECHNOLOGIES TO DEVELOP IN-HOUSE MANUFACTURING, SALES FOR CARDIOSEAL SEPTAL OCCLUDER; FIRM EXPECTS $31.8 MIL. NET PROCEEDS FROM IPO
This article was originally published in The Gray Sheet
Executive Summary
Nitinol Medical Technologies plans to develop in-house manufacturing and direct sales capabilities for the roll-out of its CardioSeal Septal Occluder, which is expected to enter European clinical trials this year, the firm says in a registration statement for an initial public offering.